Sunday, July 6, 2025 7/6/2025

Understanding and predicting relapse in acute myeloid leukemia

Award Number: R01CA175008
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2013
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Understanding and predicting relapse in acute myeloid leukemia - PROJECT SUMMARY/ABSTRACT Relapse remains the major obstacle to cure in leukemia. Why do some patients relapse, while others are cured? The ability to predict response, and intervene with alternative therapies before frank relapse occurs, can potentially optimize therapy, and potentially change the natural history of a particular patient’s disease. We will use AML as a model disease to demonstrate the power of the detection of measurable residual disease (MRD) and gene expression signatures in predicting treatment response. For these studies we will use archival and prospective samples from U.S. Intergroup studies so that we can accurately associate genetic changes with clinical characteristics and outcomes. In Aim 1 we will develop and test a new sequencing method, duplex sequencing, which can detect a mutation at a frequency of one mutant allele in a background of a million wild type alleles. In Aim 2, we will test three gene expression signatures head to head in predicting short and long- term treatment response, and discover pathways different in the response groups that may be future targets of drug therapy. In Aim 3, we will apply the above genetic tests to the allogeneic transplant setting, to predict relapse following non-myeloablative transplantation (and hence, direct abortive therapy). Our lab has had considerable success in using similar tools in CML and ALL, and indeed, MRD detection in these diseases have evolved to a surrogate for outcome in clinical trials. We likewise believe that in AML these aims will eventually allow us to predict outcome prior to therapy, pick therapies based on likely pathways responsible for the predicted unfavorable response, then monitor MRD, changing therapy early if the kinetics of MRD clearance are suboptimal.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$390 )
2024	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	11	9/13/2024	NON-COMPETING CONTINUATION	-$390
														Subtotal = -$390

Issue Date FY: 2023 ( Subtotal = $409,640 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	11	5/5/2023	NON-COMPETING CONTINUATION	$409,640
														Subtotal = $409,640

Issue Date FY: 2022 ( Subtotal = $409,640 )
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	003	10	7/1/2022	NON-COMPETING CONTINUATION	$409,640
2022	2020	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	002	9	6/15/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2020	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	9	6/3/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$53,002
2022	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	8	6/6/2022	NON-COMPETING CONTINUATION	-$53,002
2022	2020	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	005	9	8/22/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$58,688
2022	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	004	8	8/22/2022	NON-COMPETING CONTINUATION	-$58,688
														Subtotal = $409,640

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	8	5/18/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $418,000 )
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	8	4/30/2020	NON-COMPETING CONTINUATION	$418,000
														Subtotal = $418,000

Issue Date FY: 2019 ( Subtotal = $405,460 )
2019	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	7	5/16/2019	NON-COMPETING CONTINUATION	$405,460
														Subtotal = $405,460

Issue Date FY: 2018 ( Subtotal = $418,000 )
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	003	6	9/25/2018	COMPETING CONTINUATION	$14,927
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	6	6/5/2018	COMPETING CONTINUATION	$418,000
2018	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	002	5	9/25/2018	NON-COMPETING CONTINUATION	-$14,927
2018	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	5	5/31/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $418,000

Issue Date FY: 2017 ( Subtotal = $365,200 )
2017	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	5	4/27/2017	NON-COMPETING CONTINUATION	$328,680
2017	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	001	5	6/7/2017	NON-COMPETING CONTINUATION	$36,520
														Subtotal = $365,200

Issue Date FY: 2016 ( Subtotal = $365,200 )
2016	2016	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	4	4/20/2016	EXTENSION WITH OR WITHOUT FUNDS	$365,200
														Subtotal = $365,200

Issue Date FY: 2015 ( Subtotal = $365,200 )
2015	2015	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	3	4/10/2015	NON-COMPETING CONTINUATION	$365,200
														Subtotal = $365,200

Issue Date FY: 2014 ( Subtotal = $354,244 )
2014	2014	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	2	5/30/2014	NON-COMPETING CONTINUATION	$354,244
														Subtotal = $354,244

Issue Date FY: 2013 ( Subtotal = $365,200 )
2013	2013	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Cancer Detection and Diagnosis Research	000	1	6/28/2013	NEW	$365,200
														Subtotal = $365,200

Grand Total All Awards = $3,875,394

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Understanding and predicting relapse in acute myeloid leukemia

Award Number: R01CA175008

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2013

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer